← Back to Clinical Trials
Recruiting NCT05996900

NCT05996900 Investigating the Neural Mechanisms of Repetitive Brain Stimulation With Invasive and Noninvasive Electrophysiology in Humans

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05996900
Status Recruiting
Phase
Sponsor Stanford University
Condition Major Depressive Disorder
Study Type INTERVENTIONAL
Enrollment 49 participants
Start Date 2023-09-01
Primary Completion 2027-10-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Intracranial electrodesTMS

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 49 participants in total. It began in 2023-09-01 with a primary completion date of 2027-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but clinical outcome is suboptimal, partially because investigators are missing biologically-grounded brain markers which show that TMS is modifying activity at the intended target in the brain. The goal of this proposal is to characterize the key markers of the brain's response to repeated doses of TMS with high resolution using invasive brain recordings in humans, and relate these brain markers to noninvasive recordings. These markers will improve the understanding of TMS and can be used to optimize and enhance clinical efficacy for depression and other psychiatric disorders.

Eligibility Criteria

Inclusion Criteria: * Men and women, ages 18 to 65 * Medication-refractory epilepsy requiring phase II monitoring * Must have intellectual capacity to ensure adequate comprehension of the study and potential risks involved in order to provide informed consent * No current or history of major neurological disorders other than epilepsy Exclusion Criteria: * Those with a contraindication for MRIs (e.g. implanted metal) * Any unstable medical condition * Neurological or uncontrolled medical disease * Active substance abuse * Currently pregnant or breastfeeding

Contact & Investigator

Central Contact

Jade Truong

✉ kellerlab@stanford.edu

📞 (408) 840-3313

Frequently Asked Questions

Who can join the NCT05996900 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Major Depressive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05996900 currently recruiting?

Yes, NCT05996900 is actively recruiting participants. Contact the research team at kellerlab@stanford.edu for enrollment information.

Where is the NCT05996900 trial being conducted?

This trial is being conducted at Stanford, United States.

Who is sponsoring the NCT05996900 clinical trial?

NCT05996900 is sponsored by Stanford University. The trial plans to enroll 49 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology